Tirzepatide for PCOS weight loss: what the evidence actually shows

What did @lizdamyl actually say?

Pretty simply: "First place you're gonna lose weight gonna be your face." She frames a before-and-after comparison around this idea, suggesting facial fat is the first casualty of GLP-1-assisted weight loss. It's a specific, testable claim, not just vibes. And at 57K views, a lot of people heard it as medical fact rather than personal observation.

To her credit, she's sharing a personal journey, not presenting herself as a clinician. The hashtags make clear this is community content. But TikTok doesn't come with fine print, and a casual claim about fat loss sequencing can travel fast and calcify into gospel.

Does the science back this up?

Partially, but the mechanism is more complicated than "face goes first." Fat loss from caloric deficit, including the kind driven by GLP-1 agonists like tirzepatide, is largely systemic, not regionally ordered by some preset physiological queue.

That said, there is legitimate evidence that the face can show visible weight loss early and disproportionately. A 2022 study by Wollina et al. in the Journal of Cosmetic Dermatology noted that facial fat compartments, particularly in the buccal and temporal regions, are compositionally distinct and can show volume changes early in significant weight loss. Separately, work by Bertossi et al. (2019, Aesthetic Surgery Journal) documented pronounced midface volume loss in patients undergoing rapid weight reduction, sometimes ahead of other body regions in terms of visual perception. The key word there is "perception." The face is visible, expressive, and constantly photographed. You notice it first. Whether it loses fat first in absolute terms is harder to say.

What did they get wrong (or right)?

They got the intuition approximately right but overstated the certainty. Saying the face is definitively "the first place" implies a universal, reproducible biological sequence that the literature doesn't cleanly support. Fat loss distribution is influenced by genetics, sex hormones, age, and the specific medication involved.

Tirzepatide, the active ingredient in both Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist. Research from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed substantial total body weight loss averaging over 20% in some participants, but the trial didn't map regional fat loss sequencing. What we do know from body composition studies is that visceral fat, the metabolically dangerous fat around your organs, often drops early and significantly with GLP-1 therapy. That's less photogenic than a slimmer face, but arguably more important.

• Facial fat loss is real and well-documented in significant weight loss
• "First place" framing overgeneralizes individual variation
• Visceral fat loss may actually precede visible facial changes in clinical terms

What should you actually know?

If you're starting a GLP-1 medication and someone tells you your face will change first, don't bank on it, and don't panic if it doesn't. Fat loss sequencing is individual. Some people report losing facial volume noticeably early. Others lose it from the midsection, hips, or extremities first. Genetics and baseline body composition drive a lot of this.

There is also a real clinical concern worth naming: significant facial volume loss from rapid weight reduction can produce what some dermatologists now call "Ozempic face," a term covering hollowing of the cheeks and temples. This isn't dangerous, but it's worth knowing before you start. A 2023 commentary by Shafir et al. in JAMA Dermatology flagged this as an emerging aesthetic concern in GLP-1 users specifically.

Bottom line: @lizdamyl's personal experience is plausible and consistent with some evidence. But "first place you're gonna lose" is too confident a statement to make to 57,000 people without a caveat.

The PCOS angle deserves a mention

She tags PCOS, and that context matters. Polycystic ovary syndrome is associated with insulin resistance and central adiposity, and GLP-1 agonists have shown real promise in this population beyond just weight loss. A 2023 meta-analysis by Jensterle et al. in Obesity Reviews found GLP-1 receptor agonists improved both metabolic and reproductive markers in women with PCOS. Fat distribution in PCOS tends to concentrate centrally, which may actually mean facial changes are more visible relative to waist changes in this group, lending some biological plausibility to her observation even if it doesn't make it universal.